Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación

Subcutaneous immunization of leishmania HSP70-II null mutant line reduces the severity of the experimental visceral leishmaniasis in BALB/c mice

  • Solana, José Carlos
  • Ramírez, Laura
  • Cook, Emma C. L.
  • Hernández-García, Elena
  • Sacristán, Silvia
  • Martín, M. Elena
  • González, Víctor Manuel
  • Reguera, Rosa María
  • Balaña-Fouce, Rafael
  • Fresno, Manuel
  • Requena, José María
  • Iborra, Salvador
  • Soto, Manuel
Leishmania infantum parasites cause a severe form of visceral leishmaniasis in human and viscerocutaneous leishmaniasis in dogs. Recently, we reported that immunization with an attenuated L. infantum cell line, lacking the hsp70-II gene, protects against the development of murine cutaneous leishmaniasis. In this work, we analyzed the vaccine potential of this cell line towards the long-term protection against murine visceral leishmaniasis. This model shows an organ-dependent evolution of the disease. The infection can resolve in the liver but chronically affect spleen and bone marrow. Twelve weeks after subcutaneous administration of attenuated L. infantum, Bagg Albino (BALB/c) mice were challenged with infective L. infantum parasites expressing the luciferase-encoding gene. Combining in vivo bioimaging techniques with limiting dilution experiments, we report that, in the initial phase of the disease, vaccinated animals presented lower parasite loads than unvaccinated animals. A reduction of the severity of liver damage was also detected. Protection was associated with the induction of rapid parasite-specific IFN-γ production by CD4+ and CD8+ T cells. However, the vaccine was unable to control the chronic phase of the disease, since we did not find differences in the parasite burdens nor in the immune response at that time point., The research made for this study was supported in Spain by grants from Ministerio de Ciencia e Innovación FISPI11/00095, SAF2017-83575-R and FISPI14/00366 (FEDER FUNDING) and the Fondo de Investigaciones Sanitarias (ISCIII-RETICRD16/0027/0008-FEDER). S.I. is funded by RYC-2016-19463 and RTI2018-343 094484-B-I00 from Ministerio de Ciencia e Innovación. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inoculation of the Leishmania infantum HSP70-II Null Mutant Induces Long-Term Protection against L. amazonensis Infection in BALB/c Mice

  • Soto, Manuel
  • Ramírez, Laura
  • Solana, José Carlos
  • Cook, Emma C. L.
  • Hernández-García, Elena
  • Requena, José María
  • Iborra, Salvador
<i>Leishmania amazonensis</i> parasites are etiological agents of cutaneous leishmaniasis in the New World. BALB/c mice are highly susceptible to <i>L. amazonensis</i> challenge due to their inability to mount parasite-dependent IFN-γ-mediated responses. Here, we analyzed the capacity of a single administration of the <i>LiΔHSP70-II</i> genetically-modified attenuated <i>L. infantum</i> line in preventing cutaneous leishmaniasis in mice challenged with <i>L. amazonensis</i> virulent parasites. In previous studies, this live attenuated vaccine has demonstrated to induce long-protection against murine leishmaniasis due to Old World <i>Leishmania</i> species. Vaccinated mice showed a reduction in the disease evolution due to <i>L. amazonensis</i> challenge, namely reduction in cutaneous lesions and parasite burdens. In contrast to control animals, after the challenge, protected mice showed anti-<i>Leishmania</i> IgG2a circulating antibodies accompanied to the induction of <i>Leishmania</i>-driven specific IFN-γ systemic response. An analysis performed in the lymph node draining the site of infection revealed an increase of the parasite-specific IFN-ϒ production by CD4<sup>+</sup> and CD8<sup>+</sup> T cells and a decrease in the secretion of IL-10 against leishmanial antigens. Since the immunity caused by the inoculation of this live vaccine generates protection against different forms of murine leishmaniasis, we postulate <i>LiΔHSP70-II</i> as a candidate for the development of human vaccines., This research was funded by grants from Ministerio de Ciencia e Innovación FISPI11/00095 and FISPI14/00366 (FEDER FUNDING) to M.S. and RYC-2016-19463 and RTI2018-343 to S.I. J.M.R. and M.S. are funded by the Fondo de Investigaciones Sanitarias (ISCIII-RETICRD16/0027/008-FEDER). E.H.G. is supported by a FPI grant from the Spanish Ministerio de Ciencia e Innovación. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed